Menstrual-cycle restoration (return of spontaneous menses or low FSH confirming ovarian activity) is reported in 30–50% of treated women. Pregnancy achievement (either spontaneously or via assisted fertility) occurs in 15–35% of treated women across published trials, though baseline fertility potential, age, and concomitant treatments substantially influence outcomes.
Thirty-five completed trials and 3 actively recruiting trials are registered for POI cell therapy, predominantly using autologous or allogeneic placental MSCs and fetal-derived cell preparations. Trial designs vary from direct ovarian injection to systemic intravenous infusion. Outcomes tracked include restored menstruation, improved hormone levels (oestradiol, FSH), pregnancy achievement, and ultrasound evidence of follicle development. Approximately 30–50% of treated women report return of menstrual cycles within 3–6 months; pregnancy rates (per cycle or per treatment) vary widely (10–40% in published small series) and are confounded by concurrent fertility treatments (in-vitro fertilisation, egg freezing).
Являюсь ли я кандидатом? → · Premature Ovarian Insufficiency: full overview → · Стоимость Преждевременная недостаточность яичников → · Cost →
Медицинское рецензирование редакторской командой StemCellAtlas с Dr Dmytro Stoyanov (Urologist · 31+ yrs clinical practice) клиники-партнёра Stem Plus (София) в соответствии с руководствами ISSCR, FDA и EMA. Educational information, not medical advice; figures indicative.
GMP-сертифицированная регенеративная медицина в сердце ЕС — от €3 000–8 000, доля от цен США или Германии. Индивидуальные протоколы для пациентов из 50+ стран.
Бесплатная оценка врача